MDMA Successfully Treats PTSD in Another Phase 3 Trial Sponsored by MAPS
“MDMA-assisted therapy for PTSD is on track to be considered for approval by the FDA in 2024,” says MAPS founder and president Rick Doblin.
MAPS
Honest Thoughts from a Psychedelic Healer on the Psychedelic Science 2023 Summit
13,000 attendees may feel like a sea of change, but it is still a bubble in the bigger context of mainstream change.
Australia Becomes the First Country to Prescribe Psychedelics to Treat Depression and PTSD
Australia has become the first country to prescribe MDMA to treat PTSD and psilocybin to combat treatment-resistant depression.
Jaden Smith Opens Up About Psychedelics and Their Role in His Life
Jaden Smith talks about his relationship with psychedelics at the Psychedelic Science Conference in Denver.
Three Phase 3 Clinical Trials that Could Legalize Psychedelics
The road to psychedelic legalization has many paths. These 3 clinical trials have the best chances to legalize psychedelics for therapy
Canada Halts MDMA Clinical Trial Over Concerns for Participant Safety
Deficiancies in good clinical practices and accurate record keeping stops an MDMA clinical trial in its tracks
A Brief History of MDMA: From the CIA to Raves to Psychedelic Therapy
The history of MDMA is fascinating, and it is still being written.
MAPS Navigates Multiple Scandals: Why Health Canada Is Reviewing MDMA Trials
A sexual misconduct scandal, a data scandal, and an elder abuse scandal haunt psychedelics leader MAPS, currently being scrutinized by Health Canada.
5 Most Important Psychedelic Clinical Trials in 2022
Here’s why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
Can Psychedelics like MDMA Cure Eating Disorders?
Anyone who has ever suffered from an eating disorder, such…
End of content
End of content